Fig 2.
Summary of neutralization profiles of S208 and F535 variants against a panel of MAbs and entry inhibitors. (A) IC50s for each MAb or entry inhibitor against each virus are shown, with darker shading indicating more potent neutralization, as indicated in the key. MAbs b12, 2F5, and 4E10 and soluble CD4 (sCD4) were tested at a starting concentration of 25 μg/ml. MAbs VRC01, PG9, PGT121, PGT128, and PGT145 were tested at a starting concentration of 1 μg/ml. TAK-779 was tested at a starting concentration of 1 μM. Gray boxes indicate that the virus tested did not reach 50% neutralization at the highest concentration of MAb or inhibitor tested. (B) Comparison of amino acid residues that are known targets of the indicated antibodies for S208 and F535 variants. Boldface characters indicate minimum residues required for neutralization. Symbols: +, present; dot, conserved amino acid; *, presence of K168 in variant. “Shift” indicates a shift from position 332 to 334.